Score gout probability using the ACR/EULAR 2015 classification criteria with serum urate levels, joint involvement, and imaging findings.
The Gout Diagnosis Scoring Calculator implements the 2015 ACR/EULAR classification criteria for gout, providing a standardized, evidence-based approach to diagnosing this common inflammatory arthritis. With a prevalence of approximately 3.9% in the United States, gout is the most common form of inflammatory arthritis and is caused by the deposition of monosodium urate (MSU) crystals in joints and soft tissues.
The ACR/EULAR criteria use a weighted scoring system incorporating clinical features, laboratory results, and imaging findings to classify gout with high sensitivity (92%) and specificity (89%). A score of ≥ 8 out of a possible 23 points classifies an episode as gout. The gold standard remains MSU crystal identification in synovial fluid, which bypasses the scoring system entirely.
This calculator evaluates all scoring domains: joint pattern and involvement, clinical characteristics (acute onset, erythema, weight-bearing difficulty), laboratory values (serum urate levels), imaging findings (DECT, X-ray erosions), and crystal analysis. It provides a total score, classification, and estimated probability to guide clinical decision-making and treatment initiation.
This calculator standardizes gout diagnosis using the internationally validated ACR/EULAR criteria, reducing diagnostic uncertainty and helping clinicians determine when to initiate urate-lowering therapy. It is particularly valuable when joint aspiration is not performed. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
ACR/EULAR 2015 Score = Sum of weighted criteria points. Score ≥ 8 = Gout classification. Criteria include: serum urate (0–4 pts), clinical features (0–3 pts), joint pattern (0–2 pts), tophi (4 pts), imaging (0–8 pts), crystal analysis (−2 to +8 pts). Total possible: 23 points.
Result: 11 points — Gout Likely
Serum urate 8.5 mg/dL (3 pts), MTP1 involvement (2 pts), recurrent episodes (2 pts), acute onset (1 pt), erythema (1 pt), cannot bear weight (1 pt) = 10 points, well above the ≥ 8 threshold for gout classification.
Gout results from the deposition of monosodium urate crystals in joints and tissues, triggered when serum urate exceeds the physiologic saturation point of approximately 6.8 mg/dL. Over time, persistent hyperuricemia leads to crystal deposition, which can trigger intense inflammatory responses mediated by the NLRP3 inflammasome and IL-1β pathway. The disease progresses through asymptomatic hyperuricemia, acute gout flares, intercritical gout, and chronic tophaceous gout.
The differential diagnosis of acute monoarticular arthritis includes septic arthritis (which must be excluded urgently), calcium pyrophosphate deposition disease (pseudogout), reactive arthritis, and traumatic arthritis. Joint aspiration with polarized light microscopy remains the gold standard for distinguishing these conditions. MSU crystals are needle-shaped and negatively birefringent, while CPPD crystals are rhomboid and positively birefringent.
Acute gout management includes NSAIDs, colchicine, and corticosteroids. Long-term management focuses on urate-lowering therapy (ULT) to achieve target serum urate < 6 mg/dL. Allopurinol is first-line ULT, started at low dose (100 mg) and titrated. Febuxostat is second-line. Lifestyle modifications include limiting purine-rich foods, reducing alcohol consumption, and maintaining hydration.
The 2015 ACR/EULAR criteria is an evidence-based scoring system that classifies gout using clinical, laboratory, and imaging findings. A score ≥ 8 (out of 23) classifies as gout with 92% sensitivity and 89% specificity.
No, but it is the gold standard. If MSU crystals are identified in synovial fluid, the diagnosis is definitive regardless of the scoring system. The scoring criteria are most useful when aspiration is not performed.
Serum urate above 6.8 mg/dL exceeds the physiologic saturation threshold and increases crystal formation risk. However, urate levels may be normal during acute flares due to inflammatory cytokine effects on renal handling.
Current guidelines recommend a target serum urate < 6 mg/dL (< 5 mg/dL for severe tophaceous gout). This is achieved with urate-lowering therapy such as allopurinol or febuxostat.
Yes. While podagra (first MTP joint involvement) is classic, gout can affect any joint including ankles, knees, wrists, elbows, and fingers. Polyarticular gout is common in chronic disease.
Dual-energy CT (DECT) can identify urate crystal deposits non-invasively. It has high specificity (93%) for gout and is particularly useful for atypical presentations or when aspiration is not feasible.